Literature DB >> 30794467

IQGAP1, AmotL2, and FKBP51 Scaffoldins in the Glioblastoma Microenvironment.

Deborah Rotoli1,2,3,4,5, Manuel Morales6,5,7, María-Del-C Maeso8,5, Julio Ávila1,2,3, Natalia D Pérez-Rodríguez6,5, Ali Mobasheri9, Cornelis J F van Noorden10,11,12, Pablo Martín-Vasallo1,2,3.   

Abstract

Glioblastoma (GB) is the most frequently occurring and aggressive primary brain tumor. Glioma stem cells (GSCs) and astrocytoma cells are the predominant malignant cells occurring in GB besides a highly heterogeneous population of migrating, neovascularizing and infiltrating myeloid cells that forms a complex tumor microenvironment (TME). Cross talk between the TME cells is pivotal in the biology of this tumor and, consequently, adaptor proteins at critical junctions of signaling pathways may be crucial. Scaffold proteins (scaffolins or scaffoldins) integrate external and internal stimuli to regulate various signaling pathways, interacting simultaneously with multiple proteins involved. We investigated by double and triple immunofluorescence the localization of IQGAP1, AmotL2, and FKBP51, three closely related scaffoldins, in malignant cells and TME of human GB tumors. We found that IQGAP1 is preferentially expressed in astrocytoma cells, AmotL2 in GSCs, and FKBP51 in white blood cells in human GB tumors. As GSCs are specially the target for novel therapies, we will investigate in further studies whether AmotL2 inhibition is effective in the treatment of GB.

Entities:  

Keywords:  AmotL2; FKBP51; IQGAP1; astrocytoma cells; glioblastoma microenvironment; glioma stem cells; pericytes; scaffold proteins; tumor-associated macrophages (TAMs)

Mesh:

Substances:

Year:  2019        PMID: 30794467      PMCID: PMC6598128          DOI: 10.1369/0022155419833334

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  73 in total

1.  Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: its overexpression in carcinomas and association with invasion fronts.

Authors:  Kazuki Nabeshima; Yoshiya Shimao; Teruhiko Inoue; Masashi Koono
Journal:  Cancer Lett       Date:  2002-02-08       Impact factor: 8.679

2.  Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus.

Authors:  M D Galigniana; C Radanyi; J M Renoir; P R Housley; W B Pratt
Journal:  J Biol Chem       Date:  2001-02-13       Impact factor: 5.157

Review 3.  Peptidyl-prolyl isomerases: a new twist to transcription.

Authors:  Peter E Shaw
Journal:  EMBO Rep       Date:  2002-06       Impact factor: 8.807

4.  The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness.

Authors:  Tina R Hubler; Wesley B Denny; Donna L Valentine; Joyce Cheung-Flynn; David F Smith; Jonathan G Scammell
Journal:  Endocrinology       Date:  2003-06       Impact factor: 4.736

Review 5.  HIFing the brakes: therapeutic opportunities for treatment of human malignancies.

Authors:  Joseph A Garcia
Journal:  Sci STKE       Date:  2006-05-30

6.  Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains.

Authors:  Anders Bratt; William J Wilson; Boris Troyanovsky; Karin Aase; Reto Kessler; Erwin G Van Meir; Lars Holmgren; Erwin G Van Meir
Journal:  Gene       Date:  2002-09-18       Impact factor: 3.688

7.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.

Authors:  S Farzana Hussain; David Yang; Dima Suki; Kenneth Aldape; Elizabeth Grimm; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2006-06-14       Impact factor: 12.300

8.  IQGAP1 is a scaffold for mitogen-activated protein kinase signaling.

Authors:  Monideepa Roy; Zhigang Li; David B Sacks
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

10.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

View more
  3 in total

Review 1.  Cell Biology Meets Cell Metabolism: Energy Production Is Similar in Stem Cells and in Cancer Stem Cells in Brain and Bone Marrow.

Authors:  Cornelis J F van Noorden; Barbara Breznik; Metka Novak; Amber J van Dijck; Saloua Tanan; Miloš Vittori; Urban Bogataj; Noëlle Bakker; Joseph D Khoury; Remco J Molenaar; Vashendriya V V Hira
Journal:  J Histochem Cytochem       Date:  2021-10-29       Impact factor: 2.479

2.  FKBP51, AmotL2 and IQGAP1 Involvement in Cilastatin Prevention of Cisplatin-Induced Tubular Nephrotoxicity in Rats.

Authors:  Rebeca González-Fernández; María Ángeles González-Nicolás; Manuel Morales; Julio Ávila; Alberto Lázaro; Pablo Martín-Vasallo
Journal:  Cells       Date:  2022-05-09       Impact factor: 7.666

Review 3.  AmotL2, IQGAP1, and FKBP51 Scaffold Proteins in Glioblastoma Stem Cell Niches.

Authors:  Deborah Rotoli; Lucio Díaz-Flores; Ricardo Gutiérrez; Manuel Morales; Julio Ávila; Pablo Martín-Vasallo
Journal:  J Histochem Cytochem       Date:  2021-06-24       Impact factor: 2.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.